Cytomegalovirus: A Troll in the ICU? Overview of the Literature and Perspectives for the Future

Frontiers in Medicine

article

Jolien Schildermans¹  Greet De Vlieger² 

[1] Clinical Division of Intensive Care Medicine, University Hospitals Leuven;Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine

关键词: herpes virus;    cytomegalovirus;    reactivation;    critical illness;    immunoparalysis;    sepsis;   

DOI  :  10.3389/fmed.2020.00188

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Cytomegalovirus (CMV) is one of the most pathogenic viruses in human. After a primary infection, CMV resides in the host for life as a latent infection. When immunity is reduced, CMV can escape the suppressive effects of the immune system and lead to viremia and antigenemia. This reactivation, first seen in transplant patients, has also been documented in non-immunocompromised CMV-seropositive critically ill patients and is associated with higher morbidity and mortality. In the latter, it is not clear whether CMV reactivation is an innocent bystander or the cause of this observed worse outcome. Two studies showed no difference in the outcome of CMV-seropositive and seronegative patients. In addition, proof-of-concept studies investigating prophylactic antiviral treatment to prevent CMV reactivation during critical illness, failed to show a beneficial effect on interleukin levels or clinical outcome. Further research is necessary to resolve the question whether CMV replication impairs the prognosis in non-immunocompromised critically ill patients. We here give a concise overview on the available data and propose strategies to further unravel this question. First, post-mortem investigation may be useful to evaluate the effect of viral replication on organ inflammation and function. Second, further research should focus on the question whether the level of viremia needs to exceed a threshold to be associated with worse outcome. Third, clinical and biochemical assessments may help to identify patients at high risk for reactivation. Fourth, preemptive treatment based upon early detection of the virus is currently under investigation. Finally, immune-stimulating biologicals may be beneficial in high-risk groups.

【 授权许可】

CC BY